Literature DB >> 25891140

Lincosamide resistance is less frequent in Denmark in Staphylococcus pseudintermedius from first-time canine superficial pyoderma compared with skin isolates from clinical samples with unknown clinical background.

Rikke Larsen1, Lene Boysen2, June Berg2, Luca Guardabassi1, Peter Damborg1.   

Abstract

BACKGROUND: Antimicrobial resistance may be overestimated in bacterial isolates from clinical samples because veterinarians often submit samples in cases of treatment failure or recurrent cases, which are more frequently associated with resistant strains. HYPOTHESIS/
OBJECTIVES: To assess to what extent the prevalence of antimicrobial resistance in Staphylococcus pseudintermedius isolated from first-time superficial pyoderma differs from canine skin isolates from clinical samples with unknown clinical background. ANIMALS: Two study groups were enrolled in Denmark between March 2012 and October 2013: 57 dogs with first-time superficial pyoderma and no prior antimicrobial treatment (Group A); and 289 different dogs for which skin specimens were submitted for culture during the study (Group B).
METHODS: One S. pseudintermedius isolate from each dog was confirmed by MALDI-TOF mass spectrometry and tested for antimicrobial susceptibility by broth microdilution. Resistance levels in the two groups were compared by Fisher's exact test.
RESULTS: Clindamycin resistance was less frequent in Group A (14%) than in Group B (27%) (P = 0.02). Similar trends were observed for amoxicillin-clavulanic acid (1.8 versus 4.8%), chloramphenicol (8.8 versus 14.5%), enrofloxacin (1.8 versus 3.5%), oxacillin (1.8 versus 4.8%) and trimethoprim/sulfamethoxazole (3.5 versus 5.9%). Oxacillin resistance was significantly associated with resistance to six of seven non-β-lactams. CONCLUSIONS AND CLINICAL IMPORTANCE: The prevalence of lincosamide resistance is markedly influenced by patients' clinical and antimicrobial treatment history. To limit selection of multidrug-resistant bacteria, lincosamides are appropriate empirical choices for treatment of first-time superficial pyoderma even though resistance is not infrequent. Culture and susceptibility testing are, however, recommended for all pyoderma patients.
© 2015 ESVD and ACVD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25891140     DOI: 10.1111/vde.12209

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  3 in total

1.  Clindamycin resistance of skin derived Staphylococcus pseudintermedius is higher in dogs with a history of antimicrobial therapy.

Authors:  Catharina M M van Damme; Els M Broens; Silvia T Auxilia; Yvette M Schlotter
Journal:  Vet Dermatol       Date:  2020-04-22       Impact factor: 1.589

2.  Building the European Antimicrobial Resistance Surveillance network in veterinary medicine (EARS-Vet).

Authors:  Rodolphe Mader; Peter Damborg; Jean-Philippe Amat; Björn Bengtsson; Clémence Bourély; Els M Broens; Luca Busani; Paloma Crespo-Robledo; Maria-Eleni Filippitzi; William Fitzgerald; Heike Kaspar; Cristina Muñoz Madero; Madelaine Norström; Suvi Nykäsenoja; Karl Pedersen; Lucie Pokludova; Anne Margrete Urdahl; Alkiviadis Vatopoulos; Christos Zafeiridis; Jean-Yves Madec
Journal:  Euro Surveill       Date:  2021-01

3.  Review and Analysis of National Monitoring Systems for Antimicrobial Resistance in Animal Bacterial Pathogens in Europe: A Basis for the Development of the European Antimicrobial Resistance Surveillance Network in Veterinary Medicine (EARS-Vet).

Authors:  Rodolphe Mader; Cristina Muñoz Madero; Birgit Aasmäe; Clémence Bourély; Els M Broens; Luca Busani; Bénédicte Callens; Lucie Collineau; Paloma Crespo-Robledo; Peter Damborg; Maria-Eleni Filippitzi; William Fitzgerald; Annet Heuvelink; Jobke van Hout; Heike Kaspar; Madelaine Norström; Karl Pedersen; Tarja Pohjanvirta; Lucie Pokludova; Fabiana Dal Pozzo; Rosemarie Slowey; Cristiana Teixeira Justo; Anne Margrete Urdahl; Alkiviadis Vatopoulos; Christos Zafeiridis; Jean-Yves Madec; Jean-Philippe Amat
Journal:  Front Microbiol       Date:  2022-04-07       Impact factor: 6.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.